LM
Roles
Therapeutic Areas
Legend Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CARVYKTI (ciltacabtagene autoleucel) | Relapsed/Refractory Multiple Myeloma | Approved |
| LB1901 | Relapsed/Refractory T-cell Lymphoma (Adult T-cell Leukemia/Lymphoma) | Phase 1 |
| LB2102 | Extensive-Stage Small Cell Lung Cancer (SCLC) | Phase 1 |
| LB1908 | Gastric, Pancreatic, and Colorectal Cancers | Phase 1 |
| LB-ALLO1 | Relapsed/Refractory Multiple Myeloma | Pre-clinical |
Leadership Team at Legend Biotech
DY
Dr. Ying Huang
Chief Executive Officer & Chief Financial Officer
DL
Dr. Lida Pacaud
Chief Medical Officer
DF
Dr. Frank Zhang
Chief Scientific Officer
SG
Steve Gavel
Chief Commercial Officer
PB
Pranoti Bhave
Vice President, Clinical Development
DR
Dr. Robert Azelby
Chairman of the Board of Directors
DL
Dr. Lei Xiao
Founder & Director
DR
Dr. R. Keith Woods
Director
DJ
Dr. Jane Pritchett Henderson
Director
DR
Dr. Robin L. Smith
Director